fda glp-1 shortage list lawsuit Ozempic for Blindness, Stomach Paralysis and Injury Claims FDA's GLP-1 decision kicks off

Description

10.1007/s40265-020-01435-4 Drugs

While the IGF-1 and KGF pathways have been reproducibly demonstrated across multiple murine models, direct human validation of these intermediates in IBD tissue remains limited, representing a key translational gap

By comparison, this revised peak estimate is more than double the $79 billion in total sales recorded in 2025

Leading Companies Delivering GLP-1 Nutritional Support Solutions Leading Company - Nestl Health Science Industry Share - 18% In the GLP-1 nutritional support market, leading players are leveraging clinical positioning, micronutrient optimization, and bariatric-friendly formats to target consumers on GLP-1 therapies such as semaglutide and tirzepatide